MGX Company Profile and Key Details

NASDAQ : MGX

Metagenomi Common Stock

$1.41

0.02+1.44%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Metagenomi, Inc. Common Stock (MGX) stock surged +1.44%, trading at $1.41 on NASDAQ, up from the previous close of $1.39. The stock opened at $1.39, fluctuating between $1.36 and $1.45 in the recent session.

Stock Snapshot

1.39

Prev. Close

53.04M

Market Cap

1.36

Day Low

-0.6

P/E Ratio

-2.36

EPS (TTM)

N/A

Cash Flow per Share

1.39

Open

37.62M

Number of Shares

1.445

Day High

67.34%

Free Float in %

N/A

Book Value

108.69K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	1.38	1.45	1.36	1.41	108.69K
Apr 30, 2026	1.33	1.39	1.33	1.38	138.43K
Apr 29, 2026	1.43	1.43	1.34	1.35	150.28K
Apr 28, 2026	1.45	1.48	1.43	1.44	79.21K
Apr 27, 2026	1.49	1.52	1.45	1.48	94.11K
Apr 23, 2026	1.48	1.48	1.40	1.43	157.39K
Apr 22, 2026	1.51	1.52	1.44	1.48	139.03K
Apr 21, 2026	1.54	1.55	1.49	1.50	234.1K
Apr 20, 2026	1.46	1.55	1.43	1.53	355.26K
Apr 17, 2026	1.48	1.53	1.47	1.48	314.88K
Apr 16, 2026	1.41	1.45	1.40	1.44	189.4K
Apr 14, 2026	1.41	1.46	1.39	1.43	193.91K
Apr 13, 2026	1.38	1.44	1.38	1.40	130.08K
Apr 10, 2026	1.38	1.40	1.37	1.38	75.91K
Apr 09, 2026	1.36	1.41	1.35	1.39	130.43K
Apr 08, 2026	1.44	1.44	1.37	1.39	184.53K
Apr 07, 2026	1.36	1.39	1.31	1.36	132.23K
Apr 06, 2026	1.33	1.40	1.31	1.36	166.51K
Apr 02, 2026	1.27	1.37	1.27	1.35	83.12K
Apr 01, 2026	1.36	1.41	1.32	1.34	487.97K

Contact Details

Emeryville, 94608

United States

https://www.metagenomi.co 510 871 4880

About Company

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Metagenomi, Inc. Common Stock (NASDAQ:MGX) closed at $1.41 USD, gaining $0.02 (1.44%) from the previous close of $1.39. The stock is currently mid-range between its 52-week high and low $1.25 and $3.95. With a market capitalization of about $53.04 million, Metagenomi, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.65). Key stats such as the average daily volume over the past year has been around 216.53 thousand shares, volume is running light vs its 52-week average. Headquartered in Emeryville, None, Metagenomi, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jian Irish, the company employs approximately 202 people and listed since April 06, 2006. Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 6.49%, SMA50 -1.03%, SMA200 -16.49%). The stock’s 14-day RSI is 54.34 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.49% below its high and over 30.08% above its low. Average 10-day trading volume of 114.14 thousand shares is below the 3-month average of 228.02 thousand, indicating normal recent market interest.

Valuation Metrics

Metagenomi, Inc. Common Stock trades at a P/E ratio of -0.6, slightly below the S&P 500 average, with a price-to-sales ratio of 2.1 and a price-to-book ratio of 0.33 suggesting the stock is closer to book value. The P/FCF stands at -0.59, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 5.4% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $7.00. The high target offers 751.06% upside. The low target suggests 396.45% downside. The mean target is $10.00. This offers 609.22% upside. Metagenomi, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended March 05, 2026, missed forecasts by 3.45%. The prior quarter beat by -8.33%. Over the last six quarters, Apple has recorded several small beats. These include -35.71% in November 13, 2024.

Shareholding & Insider Activity

Metagenomi, Inc. Common Stock has 37.53 million shares outstanding. The public float is 25.28 million shares, elevated short interest at 5.12% of float. This equals 1.39 million shares. The short ratio is 1.59 days. Institutional investors hold 27.86% of the float. Insiders own 27.74%. Thomas Brian C. holds 2.51 million shares, Irish Jian has 333.77 thousand shares and Wapnick Pamela has 187.38 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.88 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Metagenomi Common Stock has not generated any revenue.
On valuation metrics, Metagenomi Common Stock trades at a P/E of -0.60, P/S of 2.10 and P/B of 0.33. The current ratio is 7.22 and quick ratio is 7.22. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -17.21 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.26, supported by a cash flow-to-debt ratio of -2.19.

Price Forecast & Outlook

Our AI price prediction model suggests that Metagenomi, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.55%, with price expected at $1.46 by May 18, 2026, within a range of $1.39 to $1.53 3-Month Outlook: Projected fall of -49.65%, reaching $0.71 by July 31, 2026, with a range of $0.48 to $0.79. 1-Year Outlook: Projected loss of -73.05%, with price at $0.38 by May 04, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Metagenomi, Inc. Common Stock (NASDAQ:MGX) shares are flat -0.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Metagenomi, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.6. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.46, suggesting 712.77% upside. Our AI forecast model points to short-term strength (3.55% over two weeks), a medium-term fall (-49.65% over three months), and a longer-term loss (-73.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Metagenomi, Inc. Common Stock (MGX) stock price?

Metagenomi, Inc. Common Stock (NASDAQ: MGX) stock price is $1.41 in the last trading session. During the trading session, MGX stock reached the peak price of $1.45 while $1.36 was the lowest point it dropped to. The percentage change in MGX stock occurred in the recent session was 1.44% while the dollar amount for the price change in MGX stock was $0.02.

MGX's industry and sector of operation?

The NASDAQ listed MGX is part of Biotechnology industry that operates in the broader Healthcare sector. Metagenomi, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MGX?

No Data

How MGX did perform over past 52-week?

MGX's closing price is 12.8% higher than its 52-week low of $1.25 where as its distance from 52-week high of $3.95 is -64.3%.

How many employees does MGX have?

Number of MGX employees currently stands at 202.

Link for MGX official website?

Official Website of MGX is: https://www.metagenomi.co

How do I contact MGX?

MGX could be contacted at phone 510 871 4880 and can also be accessed through its website. MGX operates from 5959 Horton Street, Emeryville, 94608, United States.

How many shares of MGX are traded daily?

MGX stock volume for the day was 108.69K shares. The average number of MGX shares traded daily for last 3 months was 216.53K.

What is the market cap of MGX currently?

The market value of MGX currently stands at $53.04M with its latest stock price at $1.41 and 37.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	202
Beta	0.57
Sales or Revenue	N/A
5Y Sales Change%	28.145%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MGX Company Profile and Key Details

Metagenomi Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook